Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Adc Therapeutics Sa (NY: ADCT ) 2.950 +0.130 (+4.61%) Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Adc Therapeutics Sa < Previous 1 2 3 4 Next > ADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q2 2024 August 06, 2024 ADCT stock results show that ADC Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. Via InvestorPlace 7 Growth Stocks to Buy for Under $5 for Massive Gains July 11, 2024 Although growth stocks under $5 are inherently risky and unpredictable, their very nature also facilitates robust upside potential. Via InvestorPlace Intapp, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session July 08, 2024 Via Benzinga Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget June 13, 2024 Since wealth without health is utterly meaningless, investors may have some confidence with these biotech stocks to buy. Via InvestorPlace ADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q1 2024 May 06, 2024 ADCT stock results show that ADC Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace A Preview Of ADC Therapeutics's Earnings March 12, 2024 Via Benzinga ADC Therapeutics - Time For A Turn-Around? February 27, 2024 ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. Via Talk Markets Analyst Expectations for ADC Therapeutics's Future November 20, 2023 Via Benzinga The Latest Analyst Ratings for ADC Therapeutics September 12, 2023 Via Benzinga BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session May 06, 2024 Via Benzinga Medifast Reports Mixed Results, Joins Coursera, Chegg And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session April 30, 2024 Via Benzinga Dollar Tree Reports Weak Earnings, Joins Tesla, Arcos Dorados And Other Big Stocks Moving Lower On Wednesday March 13, 2024 U.S. stocks were mixed, with the Dow Jones index surging more than 100 points on Wednesday. Via Benzinga Topics Stocks Exposures US Equities Alaska Air To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday February 20, 2024 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga A Preview Of ADC Therapeutics's Earnings August 07, 2023 Via Benzinga 4 Analysts Have This to Say About ADC Therapeutics July 25, 2023 Via Benzinga Earnings Scheduled For March 13, 2024 March 13, 2024 Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. Via Benzinga The 3 Biotech Stocks That Could Make Your February Unforgettable February 15, 2024 After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks. Via InvestorPlace The 3 Most Undervalued Biotech Stocks to Buy in February 2024 February 08, 2024 With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider. Via InvestorPlace Why BEST Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket November 06, 2023 Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares surged 358% to $134.37 in pre-market trading after gaining 100% on Friday. The company’s stock began trading on Friday following merger... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023 August 10, 2023 Via Benzinga Stocks That Hit 52-Week Lows On Tuesday July 25, 2023 On Tuesday, 56 companies set new 52-week lows. Via Benzinga Stocks That Hit 52-Week Lows On Friday July 21, 2023 On Friday, 54 companies hit new 52-week lows. Via Benzinga Stocks That Hit 52-Week Lows On Monday July 24, 2023 On Monday morning, 70 companies achieved new lows for the year. Via Benzinga ADC Therapeutics Pulls Plug On Mid-Stage Zynlonta Study In Untreated Lymphoma Patients After Patient Deaths July 21, 2023 ADC Therapeutics SA (NASDAQ: ADCT) announced that it plans to discontinue the Phase 2 LOTIS-9 trial evaluating Zynlonta (loncastuximab tesirine-lpyl) and rituximab in unfit or frail patients with... Via Benzinga Dow Rises More Than 200 Points; Adial Pharmaceuticals Shares Spike Higher July 11, 2023 U.S. stocks traded higher toward the end of trading, with the Dow Jones surging more than 200 points on Tuesday. The Dow traded up 0.73% to 34,193.60 while the NASDAQ rose 0.25% to 13,720.16. The S&P... Via Benzinga Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session July 11, 2023 Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares climbed 129.5% to $8.01 after gaining 9% on Monday. Via Benzinga Crude Oil Rises 2%; ADC Therapeutics Shares Plummet July 11, 2023 U.S. stocks traded higher midway through trading, with the Dow Jones surging over 100 points on Tuesday. The Dow traded up 0.41% to 34,082.47 while the NASDAQ rose 0.29% to 13,725.52. The S&P 500, also... Via Benzinga Dow Jumps Over 100 Points; US Small Business Optimism Index Tops Estimates July 11, 2023 U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.40% to 34,080.13 while the NASDAQ rose 0.23% to... Via Benzinga ADC Therapeutics Stock Is Plunging Today - What's Going On? July 11, 2023 ADC Therapeutics SA (NASDAQ: ADCT) has voluntarily paused enrollment of new patients in the Phase 2 LOTIS-9 trial evaluating Zynlonta (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023 April 24, 2023 Via Benzinga < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
